AbbVie tries a new approach in 340B programme battle
AbbVie has opened a new front in the pharma industry's battle to reform the 340B drug discounting programme for safety net hospitals in the US.
Newsletters and Deep Dive digital magazine
AbbVie has opened a new front in the pharma industry's battle to reform the 340B drug discounting programme for safety net hospitals in the US.
Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been blocked in the courts.
A change to the ACIP charter has raised concerns of even greater political influence over the vaccine panel by HHS Secretary Kennedy.
One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Editor's Picks
Newsletters and Deep Dive
digital magazine